Dr Colaco trained in clinical oncology at the Christie before undertaking specialist fellowships in the USA at the University of Florida Proton Therapy Institute and Yale University. He was the first UK doctor to train in proton therapy, spending 12 months at the Florida Proton Therapy Institute where in addition to treating patients with proton therapy he also published several peer-reviewed manuscripts on proton therapy research in international journals.
Following this, he was the first doctor selected to undertake a year-long period of training in stereotactic radiosurgery and stereotactic radiotherapy at Yale University working with both the Gamma Knife and Cyberknife and gaining expertise in the stereotactic treatment of brain, bone and spine metastases. At Yale, he also published several peer reviewed manuscripts on stereotactic radiotherapy and radiosurgery.
He was appointed as a consultant at the Christie on his return to the UK and has been involved in the development of The Christie Proton Therapy centre with a leading role in the development of treatment protocols for proton therapy.
He was principal investigator at the Christie for the CORE trial examining the role of stereotactic radiotherapy in metastatic lung, breast and prostate cancer and also leads the development of the stereotactic radiotherapy for oligo-metastasis at the Christie.
As a member of the UK SABR consortium committee, Dr Colaco is involved in development of stereotactic radiotherapy for oligo metastatic disease nationally. He also specialises in stereotactic radiosurgery to metastatic brain tumours, proton therapy to primary brain tumours and conventional radiotherapy and chemotherapy for primary brain tumours.